Taxotere-Enoxaparin-(ENOXA)-Study

Summary

Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as single therapy or in combination with Enoxaparin in patients aged older than 18 years with locally advanced or metastatic non-small cell lung cancer (stadium IIIb/IV), a phase III study. Study hypothesis: Increase of progressive free survival from 5 to 7.5 months.

Timeline

Start

2009-11

Primary completion

2011-02

Completion

2011-02

Drugs

Indications